drugset / Trial / NCT00698334

Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis

NCT00698334 ↗

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Tuberculosis (TB) is the most common opportunistic infection among HIV infected persons living in developing countries. Directly observed treatment, short-course (DOTS) is the internationally recommended strategy for the treatment of TB. However, the efficacy of DOTS for the treatment of HIV-associated TB is not well studied. This study aims to compare the efficacy of thrice weekly DOTS in HIV-infected versus HIV-negative patients with TB.

Timeline

Start
2006-04
Primary completion
2010-09
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ethambutol Small molecule 1200 mg —
Comparator INH Unknown 600 mg —
Comparator Pyrazinamide Small molecule 1500 mg —
Comparator Rifampicin Small molecule 450 mg —
Comparator Rifampicin Small molecule 600 mg —

Indications